These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

235 related articles for article (PubMed ID: 37130682)

  • 1. Faecal microbiota transplantation to prevent complications after allogeneic stem cell transplantation for haematological malignancies: a study protocol for a randomised controlled phase-II trial (the FMT-allo study).
    Dougé A; Ravinet A; Corriger A; Cabrespine A; Wasiak M; Pereira B; Sokol H; Nguyen S; Bay JO
    BMJ Open; 2023 May; 13(5):e068480. PubMed ID: 37130682
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Addition of sirolimus to standard cyclosporine plus mycophenolate mofetil-based graft-versus-host disease prophylaxis for patients after unrelated non-myeloablative haemopoietic stem cell transplantation: a multicentre, randomised, phase 3 trial.
    Sandmaier BM; Kornblit B; Storer BE; Olesen G; Maris MB; Langston AA; Gutman JA; Petersen SL; Chauncey TR; Bethge WA; Pulsipher MA; Woolfrey AE; Mielcarek M; Martin PJ; Appelbaum FR; Flowers MED; Maloney DG; Storb R
    Lancet Haematol; 2019 Aug; 6(8):e409-e418. PubMed ID: 31248843
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of two different doses of rabbit anti-T-lymphocyte globulin to prevent graft-versus-host disease in children with haematological malignancies transplanted from an unrelated donor: a multicentre, randomised, open-label, phase 3 trial.
    Locatelli F; Bernardo ME; Bertaina A; Rognoni C; Comoli P; Rovelli A; Pession A; Fagioli F; Favre C; Lanino E; Giorgiani G; Merli P; Pagliara D; Prete A; Zecca M
    Lancet Oncol; 2017 Aug; 18(8):1126-1136. PubMed ID: 28705454
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Safety and efficacy of post-haematopoietic cell transplantation maintenance therapy with blinatumomab for relapsed/refractory CD19-positive B-cell acute lymphoblastic leukaemia: protocol for a phase I-II, multicentre, non-blinded, non-controlled trial (JPLSG SCT-ALL-BLIN21).
    Sakaguchi H; Umeda K; Kato I; Sakaguchi K; Hiramatsu H; Ishida H; Yabe H; Goto H; Kawahara Y; Yamashita YI; Sanada M; Deguchi T; Takahashi Y; Saito A; Noma H; Horibe K; Taga T; Adachi S;
    BMJ Open; 2023 Apr; 13(4):e070051. PubMed ID: 37068890
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Could enteral nutrition improve the outcome of patients with haematological malignancies undergoing allogeneic haematopoietic stem cell transplantation? A study protocol for a randomized controlled trial (the NEPHA study).
    Lemal R; Cabrespine A; Pereira B; Combal C; Ravinet A; Hermet E; Bay JO; Bouteloup C
    Trials; 2015 Apr; 16():136. PubMed ID: 25872934
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety and Efficacy of Fecal Microbiota Transplantation for Grade IV Steroid Refractory GI-GvHD Patients: Interim Results From FMT2017002 Trial.
    Zhao Y; Li X; Zhou Y; Gao J; Jiao Y; Zhu B; Wu D; Qi X
    Front Immunol; 2021; 12():678476. PubMed ID: 34220825
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Addition of anti-thymocyte globulin to standard graft-versus-host disease prophylaxis versus standard treatment alone in patients with haematological malignancies undergoing transplantation from unrelated donors: final analysis of a randomised, open-label, multicentre, phase 3 trial.
    Walker I; Panzarella T; Couban S; Couture F; Devins G; Elemary M; Gallagher G; Kerr H; Kuruvilla J; Lee SJ; Moore J; Nevill T; Popradi G; Roy J; Schultz KR; Szwajcer D; Toze C; Foley R;
    Lancet Haematol; 2020 Feb; 7(2):e100-e111. PubMed ID: 31958417
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Standard graft-versus-host disease prophylaxis with or without anti-T-cell globulin in haematopoietic cell transplantation from matched unrelated donors: a randomised, open-label, multicentre phase 3 trial.
    Finke J; Bethge WA; Schmoor C; Ottinger HD; Stelljes M; Zander AR; Volin L; Ruutu T; Heim DA; Schwerdtfeger R; Kolbe K; Mayer J; Maertens JA; Linkesch W; Holler E; Koza V; Bornhäuser M; Einsele H; Kolb HJ; Bertz H; Egger M; Grishina O; Socié G;
    Lancet Oncol; 2009 Sep; 10(9):855-64. PubMed ID: 19695955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gut microbiota injury in allogeneic haematopoietic stem cell transplantation.
    Shono Y; van den Brink MRM
    Nat Rev Cancer; 2018 May; 18(5):283-295. PubMed ID: 29449660
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessing the impact on intestinal microbiome and clinical outcomes of antibiotherapy optimisation strategies in haematopoietic stem cell transplant recipients: study protocol for the prospective multicentre OptimBioma study.
    Jiménez-Jorge S; Labrador-Herrera G; Rosso-Fernández CM; Rodríguez-Torres N; Pachón-Ibáñez ME; Smani Y; Márquez-Malaver FJ; Limón Ramos C; Solano C; Vázquez-López L; Kwon M; Mora Barrios JM; Aguilar-Guisado M; Espigado I;
    BMJ Open; 2020 Jul; 10(7):e034570. PubMed ID: 32690735
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Extracorporeal Photopheresis as Graft-versus-Host Disease Prophylaxis: A Randomized Controlled Trial.
    Ali MM; Gedde-Dahl T; Osnes LT; Perrier F; Veierød MB; Tjønnfjord GE; Iversen PO
    Transplant Cell Ther; 2023 Jun; 29(6):364.e1-364.e11. PubMed ID: 36878428
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hematopoietic stem cell transplantation using single UM171-expanded cord blood: a single-arm, phase 1-2 safety and feasibility study.
    Cohen S; Roy J; Lachance S; Delisle JS; Marinier A; Busque L; Roy DC; Barabé F; Ahmad I; Bambace N; Bernard L; Kiss T; Bouchard P; Caudrelier P; Landais S; Larochelle F; Chagraoui J; Lehnertz B; Corneau S; Tomellini E; van Kampen JJA; Cornelissen JJ; Dumont-Lagacé M; Tanguay M; Li Q; Lemieux S; Zandstra PW; Sauvageau G
    Lancet Haematol; 2020 Feb; 7(2):e134-e145. PubMed ID: 31704264
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In-vivo T-cell depleted reduced-intensity conditioned allogeneic haematopoietic stem-cell transplantation for patients with acute lymphoblastic leukaemia in first remission: results from the prospective, single-arm evaluation of the UKALL14 trial.
    Marks DI; Clifton-Hadley L; Copland M; Hussain J; Menne TF; McMillan A; Moorman AV; Morley N; Okasha D; Patel B; Patrick P; Potter MN; Rowntree CJ; Kirkwood AA; Fielding AK
    Lancet Haematol; 2022 Apr; 9(4):e276-e288. PubMed ID: 35358442
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
    Petersen SL
    Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Corticosteroids for preventing graft-versus-host disease after allogeneic myeloablative stem cell transplantation.
    Quellmann S; Schwarzer G; Hübel K; Greb A; Engert A; Bohlius J
    Cochrane Database Syst Rev; 2008 Jul; (3):CD004885. PubMed ID: 18646116
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Significant Risk of Graft-versus-Host Disease with Exposure to Checkpoint Inhibitors before and after Allogeneic Transplantation.
    Ijaz A; Khan AY; Malik SU; Faridi W; Fraz MA; Usman M; Tariq MJ; Durer S; Durer C; Russ A; Parr NNC; Baig Z; Sagar F; Ali Z; McBride A; Anwer F
    Biol Blood Marrow Transplant; 2019 Jan; 25(1):94-99. PubMed ID: 30195074
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Clinical study of 19 cases of steroid-refractory gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation with fecal microbiota transplantation].
    Zheng YY; Yang XT; Lin GQ; Bian MR; Si YJ; Zhang XX; Zhang YM; Wu DP
    Zhonghua Xue Ye Xue Za Zhi; 2023 May; 44(5):401-407. PubMed ID: 37550190
    [No Abstract]   [Full Text] [Related]  

  • 18. Acute GVHD prophylaxis plus ATLG after myeloablative allogeneic haemopoietic peripheral blood stem-cell transplantation from HLA-identical siblings in patients with acute myeloid leukaemia in remission: final results of quality of life and long-term outcome analysis of a phase 3 randomised study.
    Bonifazi F; Solano C; Wolschke C; Sessa M; Patriarca F; Zallio F; Nagler A; Selleri C; Risitano AM; Messina G; Bethge W; Herrera P; Sureda A; Carella AM; Cimminiello M; Guidi S; Finke J; Sorasio R; Ferra C; Sierra J; Russo D; Benedetti E; Milone G; Benedetti F; Heinzelmann M; Pastore D; Jurado M; Terruzzi E; Narni F; Völp A; Ayuk F; Ruutu T; Kröger N
    Lancet Haematol; 2019 Feb; 6(2):e89-e99. PubMed ID: 30709437
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mocravimod, a Selective Sphingosine-1-Phosphate Receptor Modulator, in Allogeneic Hematopoietic Stem Cell Transplantation for Malignancy.
    Dertschnig S; Gergely P; Finke J; Schanz U; Holler E; Holtick U; Socié G; Medinger M; Passweg J; Teshima T; Stylianou C; Oehen S; Heim D; Bucher C
    Transplant Cell Ther; 2023 Jan; 29(1):41.e1-41.e9. PubMed ID: 36343893
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Fecal microbiota transfer for refractory intestinal graft-versus-host disease - Experience from two German tertiary centers.
    Goeser F; Sifft B; Stein-Thoeringer C; Farowski F; Strassburg CP; Brossart P; Higgins PG; Scheid C; Wolf D; Holderried TAW; Vehreschild MJGT; Cruz Aguilar MR
    Eur J Haematol; 2021 Aug; 107(2):229-245. PubMed ID: 33934412
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.